SCLStepan Company
Is the price fair?
A demanding price: priced for +13% a year vs −2% a year delivered, at the top of its own P/E range, and rich vs its sector.
Priced for ~13% a year FCF growth. The price already bakes in strong, sustained growth.
Expensive vs its own history: P/E 22.8 vs a 18.8 median over 39 quarters (+21% vs median).
Sector median 18.9× across 51 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SCL's price assumes
Stepan Company did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.52× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.9%
Free cash flow yield · Specialty Chemicals median 4.7%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; revenue has grown −1.9% a year over the last three.
- Price / book
- 1.04
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.04
- EV / EBIToperating margin 0.82%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.74
- Free cash flow, trailing twelve months
- $37M
- Market capitalisation
- $1.26B
- 3-year revenue growth
- −1.9%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Specialty Chemicals
Ranks #27 of 33 by RyuScore